

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6018822

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT	03/10/2020

RECEIVING PARTY DATA

Name:	COVIS PHARMA B.V.
Street Address:	GRAFENAUWEG 12
City:	ZUG
State/Country:	SWITZERLAND
Postal Code:	CH-6300

PROPERTY NUMBERS Total: 30

Property Type	Number
Patent Number:	6350768
Patent Number:	6660757
Patent Number:	6245791
Patent Number:	7041661
Patent Number:	6642262
Patent Number:	7468433
Patent Number:	6767901
Patent Number:	8383611
Patent Number:	9422327
Patent Number:	8486923
Patent Number:	7879832
Patent Number:	8258124
Patent Number:	7879833
Patent Number:	8268240
Patent Number:	8182824
Patent Number:	8435497
Patent Number:	8371292
Patent Number:	8464707
Patent Number:	8288445
Patent Number:	7947744

PATENT

Property Type	Number
Patent Number:	8481516
Patent Number:	8029811
Patent Number:	8163299
Patent Number:	8440210
Patent Number:	7736673
Application Number:	13688659
Application Number:	13744962
Application Number:	11578294
Application Number:	14865637
Application Number:	14238055

CORRESPONDENCE DATA

Fax Number: (202)835-7586

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-835-7500

Email: dcip@milbank.com

Correspondent Name: JAVIER J. RAMOS

Address Line 1: 1850 K STREET, NW., SUITE 1100

Address Line 2: MILBANK, LLP

Address Line 4: WASHINGTON, D.C. 20006

ATTORNEY DOCKET NUMBER:	34408.00024
NAME OF SUBMITTER:	JAVIER J. RAMOS
SIGNATURE:	/Javier J. Ramos/
DATE SIGNED:	03/17/2020

Total Attachments: 4

source=Covis - Patent Release (Execution Version)#page1.tif

source=Covis - Patent Release (Execution Version)#page2.tif

source=Covis - Patent Release (Execution Version)#page3.tif

source=Covis - Patent Release (Execution Version)#page4.tif

RELEASE OF SECURITY INTEREST IN PATENTS

March 10, 2020

WHEREAS, pursuant to that certain U.S. Short-Form Patents Security Agreement, dated as of December 4, 2018 (the “Patent Security Agreement”), recorded in the United States Patent and Trademark Office (“USPTO”) on December 20, 2018 under Reel/Frame 047834/0926, by COVIS PHARMA B.V. (“Releasee”) to CAPITAL ONE, NATIONAL ASSOCIATION, as collateral agent (“Releasor”), Releasee granted to Releasor, for the benefit of the Secured Parties (as defined in the Patent Security Agreement), a continuing security interest in all of its right, title and interest in, to and under all of Releasee’s patents used by, and patent applications filed with the USPTO, including, without limitation, the patents and applications listed on the annexed Schedule A, all related patents and applications thereto, including all issuances, continuations, continuations-in-part, revisions, extensions, re-examinations thereof, any patents and patent applications claiming priority to said patents and patent applications or from which said patents and patent applications claim priority, and pending applications associated therewith and all proceeds thereof, including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages arising from past, present and future violations thereof (collectively, the “Patent Collateral”); and

WHEREAS, Releasee has requested, and Releasor has agreed to execute, acknowledge and deliver, this Release of Security Interest in Patents to terminate the Patent Security Agreement and confirm the release, relinquishment and discharge of its continuing security interest in, to and under the Patent Collateral.

NOW, THEREFORE, in consideration of and in exchange for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, Releasor hereby agrees as follows:

Release of Security Interest. Releasor hereby, without any representation or warranty and without any recourse to Releasor, terminates the Patent Security Agreement and hereby terminates, releases, relinquishes and discharges its continuing security interest in, to and under the Patent Collateral and transfers and assigns to Releasee any right, title or interest Releasor may have in, to and under the Patent Collateral.

The Releasor further agrees to execute and deliver to the Releasee any and all further documents and instruments, and do any and all further acts which the Releasee (or its agents or designees) reasonably request, at the Releasee’s sole cost and expense, in order to confirm this Release of Security Interest in Patents and the Releasee’s right, title, and interest in or to the Patent Collateral.

THIS RELEASE OF SECURITY INTEREST IN PATENTS SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK.

[Remainder of page intentionally left blank.]

IN WITNESS WHEREOF, Releasor has caused this Release of Security Interest in Patents to be duly executed as of the date first written above.

CAPITAL ONE, NATIONAL ASSOCIATION,
as Collateral Agent

By: 
Name: Anthony B. Sendik
Title: Duly Authorized Signatory

[Signature Page to Patent Security Release]

PATENT
REEL: 052142 FRAME: 0964

SCHEDULE A**PATENTS****Patent Registrations**

Title	Application Number	Filing Date	Patent Number	Issue Date	Expiration Date	Owner
COMBINATION OF RILUZOLE AND OF GABAPENTIN AND ITS USE AS A MEDICAMENT	09/718,543	11/22/2000	6,350,768	02/26/2002	11/22/2020	Covis Pharma S.A.R.L.
USE OF RILUZOLE IN THE TREATING ACOUSTIC TRAUMAS	09/882,223	06/15/2001	6,660,757	12/09/2003	12/13/2019	Covis Pharma S.A.R.L.
USE OF 2-AMINO-6-TRIFLUOROMETHOXYBENZOTHIAZOLE FOR THE PREVENTION OR TREATMENT OF CEREBELLAR DYSFUNCTION	09/631,798	08/03/2000	6,245,791	06/12/2001	02/03/2019	Covis Pharma S.A.R.L.
USE OF THIAZOLOBENZOHETEROCYCLES FOR TREATING MULTIPLE SCLEROSIS	10/737,634	12/16/2003	7,041,661	05/09/2006	03/02/2024	Covis Pharma S.A.R.L.
RILUZOLE AND ALPHA-TOCOPHEROL COMBINATION	09/854,318	05/11/2001	6,642,262	11/04/2003	04/10/2020	Covis Pharma S.A.R.L.

Case Reference	Country	Application No.	Grant No.	Expiry Date
TAK1009-US-PCT	United States Of America	10/399689	7468433	06 November 2021
TAK1078-US-PCT	United States Of America	10/110629	6767901	20 October 2020
TAK1081-US-CNT	United States Of America	13/688659	Application published. Grant pending.	20 October 2020
TAK1081-US-PCT	United States Of America	10/110632	8383611	20 October 2020

TAK1112-US-PCT	United States Of America	10/549631	9422327	26 March 2024
TAK1124-US-CNT	United States Of America	12/973414	8486923	29 August 2023
TAK1124-US-PCT	United States Of America	10/524821	7879832	29 August 2023
TAK1156-US-CNT	United States Of America	12/973350	8258124	11 December 2023
TAK1156-US-PCT	United States Of America	10/537356	7879833	11 December 2023
TAK1170-US-PCD	United States Of America	12/461647	8268240	02 July 2023
TAK1170-US-PCT	United States Of America	10/519484	8182824	02 July 2023
TAK1199-US-PCT	United States Of America	10/559383	8435497	09 June 2024
TAK1231-US-CNT	United States Of America	13/744962	Under appeal	15 September 2024
TAK1231-US-PCT	United States Of America	10/571311	8371292	15 September 2024
TAK1232-US-PCT	United States Of America	11/578294	Application published; grant pending	19 April 2025
TAK1235-US-PCT	United States Of America	10/572316	8464707	22 September 2024
TAK1245-US-PCD	United States Of America	14/865637	Application published; Grant pending	15 December 2024
TAK1465-US-CNT	United States Of America	12/951608	8288445	08 July 2024
TAK1465-US-PCT	United States Of America	11/325875	7947744	08 July 2024
TAK1538-US-PCT	United States Of America	12/448351	8481516	26 December 2027
TAK1587-US-CNT	United States Of America	12/771557	8029811	27 March 2024
TAK1587-US-CNT[2]	United States Of America	13/219046	8163299	27 March 2024
TAK1587-US-CNT[3]	United States Of America	13/437569	8440210	27 March 2024
TAK1587-US-PCT	United States Of America	11/259495	7736673	27 March 2024
TAK1700-US-PCT	United States Of America	14/238055	Application filed	13 August 2032